Geulah Livshits
Stock Analyst at Chardan Capital
(4.31)
# 345
Out of 5,170 analysts
258
Total ratings
45.53%
Success rate
19.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $4.58 | +162.01% | 18 | Mar 19, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $26 | $8.80 | +195.45% | 15 | Mar 19, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $210 | $113.12 | +85.64% | 8 | Mar 16, 2026 | |
| SLDB Solid Biosciences | Maintains: Buy | $15 | $7.07 | +112.16% | 10 | Mar 12, 2026 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $8 | $0.77 | +936.00% | 15 | Mar 12, 2026 | |
| EDIT Editas Medicine | Maintains: Buy | $3.5 | $2.34 | +49.57% | 11 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $26 → $27 | $13.01 | +107.53% | 19 | Mar 2, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $220 → $323 | $253.92 | +27.21% | 15 | Feb 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $74 → $76 | $46.86 | +62.19% | 17 | Feb 17, 2026 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $17 | $5.72 | +197.20% | 14 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $13 | $0.88 | +1,379.12% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 | $9.69 | +158.13% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $4.83 | +314.51% | 15 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $21 | $7.00 | +200.21% | 6 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $3.64 | +147.59% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $3.80 | +347.96% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $4.38 | +151.14% | 22 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.44 | +663.84% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.51 | +139.04% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.34 | +458.58% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.01 | +298.67% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $51.68 | +302.48% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.61 | +2,521.23% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $8.23 | +993.56% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.70 | +8.11% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $20.42 | -11.85% | 1 | Oct 27, 2020 |
Taysha Gene Therapies
Mar 19, 2026
Maintains: Buy
Price Target: $12
Current: $4.58
Upside: +162.01%
4D Molecular Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $26
Current: $8.80
Upside: +195.45%
Palvella Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $210
Current: $113.12
Upside: +85.64%
Solid Biosciences
Mar 12, 2026
Maintains: Buy
Price Target: $15
Current: $7.07
Upside: +112.16%
Tenaya Therapeutics
Mar 12, 2026
Maintains: Buy
Price Target: $8
Current: $0.77
Upside: +936.00%
Editas Medicine
Mar 9, 2026
Maintains: Buy
Price Target: $3.5
Current: $2.34
Upside: +49.57%
Intellia Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $26 → $27
Current: $13.01
Upside: +107.53%
Krystal Biotech
Feb 18, 2026
Maintains: Buy
Price Target: $220 → $323
Current: $253.92
Upside: +27.21%
CRISPR Therapeutics AG
Feb 17, 2026
Maintains: Buy
Price Target: $74 → $76
Current: $46.86
Upside: +62.19%
Lexeo Therapeutics
Jan 13, 2026
Maintains: Buy
Price Target: $17
Current: $5.72
Upside: +197.20%
Dec 9, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $0.88
Upside: +1,379.12%
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $9.69
Upside: +158.13%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.83
Upside: +314.51%
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $7.00
Upside: +200.21%
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.64
Upside: +147.59%
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $3.80
Upside: +347.96%
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $4.38
Upside: +151.14%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.44
Upside: +663.84%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.51
Upside: +139.04%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.34
Upside: +458.58%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $3.01
Upside: +298.67%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $51.68
Upside: +302.48%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.61
Upside: +2,521.23%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $8.23
Upside: +993.56%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.70
Upside: +8.11%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $20.42
Upside: -11.85%